Brussels, 10 April 2018 – A brand new collaboration between 34 public and private partners was launched today, with the aim to make meaningful patient engagement in the life cycle of medicines a reality. PARADIGM stands for Patients Active in Research and Dialogues for an Improved Generation of Medicines and is funded by the Innovative Medicines Initiative.
The PARADIGM consortium is led by European Patients’ Forum and EFPIA and comprises a mix of partners from patient organisations, regulatory bodies, universities, non-for-profit organisations, SMEs, trade associations to pharmaceutical companies. PARADIGM is a public private partnership funded by the Innovative Medicines Initiative and EFPIA members. It was launched on 1 March 2018 and will run for 30 months, until August 2020.
Patient engagement in biomedical research is key for better health outcomes. PARADIGM will build on existing tools, fill knowledge gaps, define how to make all tools available to those who need them, raise awareness amongst those who think they don’t need them and build a sustainable roadmap for patient engagement.
At the end of the 30 months life span of the project, patients and researchers will have access to a framework that allows structured, meaningful, sustainable and ethical patient engagement throughout three key decision-making points of the development of medicinal products: the research priority setting; the design of clinical trials and the early dialogues with regulators and HTA bodies.
To achieve these ambitious goals, PARADIGM is joining forces with other patient engagement initiatives, and organises the First Open Forum on Patient Engagement with EUPATI (European Patients’ Academy on Therapeutic Innovation) and PFMD (Patient Focused Medicines Development).